

Emergency Submission to Supplement OMB Control Number 0920-0821 in the context of Active Monitoring of Travelers Coming from Sierra Leone, Liberia, and Guinea

Supporting Statement B

Respondent universe:

This package is structured to collect information of all travelers coming from countries currently affected by the Ebola outbreak. As of now, those countries include Sierra Leone, Liberia, and Guinea.

Data Collection Methods:

Active monitoring will be conducted on every traveler arriving at a U.S. airport from countries affected by the Ebola outbreak. During entry screening, travelers will be provided educational material about Ebola and a CARE card which include the IVR number and a unique ID. Customs and Border Patrol agents will affix a sticker with the CARE ID that corresponds to the ID on the CARE card to the Traveler Health Declaration Form at the time of entry screening. The ID will be added to the Quarantine Activity Reporting System (QARS) along with the other information from the form. Travelers will call an Interactive Voice Response (IVR) System, enter their CARE ID, and then move through a series of questions about the development of fever or other symptoms indicative of Ebola. A French version of the script will be available for those travelers who request it. The traveler will be asked if they checked their temperature and if they have, they will be advanced to two questions about the presence of a temperature over 100.4 F and the presence of other symptoms indicative of possible exposure to Ebola.

If the traveler reports a fever or other symptom, the system will immediately advance them to a live call center representative. If a traveler reports “no” to both questions, the call will end and their responses will be saved with their ID number. Upon receipt of the data, CDC will match CARE IDs from the Traveler Health Declaration Form to identify the jurisdiction associated with each CARE ID. Upon request, states will be provided with an Excel file at a frequency of their preference that indicates which CARE IDs have reported in and their symptom-development status.